Sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus

Sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus Dhanush Bellapu Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, VISTAS, Chennai, Tamil Nadu, India Ronald Darwin Department of Pharmacology, School of Pharmaceutical Sciences, VISTAS, Chennai, Tamil Nadu, India INTRODUCTION:

SGLT2 inhibitors have a wide extent of restorative movement and higher chance of hypoglycemia because of their affront autonomous action in treating type 2 diabetes. SGLT2 inhibitors have great security and resistance when utilized as monotherapy or in conjunction with other oral hypoglycemic medicines. Since SGLT2 inhibitors can cause hyperglycemia, which results in vaginal and urinary tract infection contaminations. When compared, dapagliflozin had higher contaminations. The key issue displayed is that ketoacidosis and that it may take a little time to analyze it.
OBJECTIVES:

To compare the security of canagliflozin and dapagliflozin by watching the long-term impacts on the urinary volume, changes in renal status, and metabolic changes.
RESEARCH METHODOLOGY:

A Planned Interventional Comparative Ponder conducted among 1726 patients who were conceded to in the General Medicine and Endocrine Departments, Anu Group of hospitals, Vijayawada over 12 months from December 2021 to December 2022. By alluding to the patient’s fasting blood sugar and postprandial blood sugar, renal function test, glycated hemoglobin, blood pressure, and the finding seriousness score of adverse drug reaction (ADR) utilizing Naranjo scale.
RESULTS:

Patients had most common ADRs after utilizing Canagliflozin and Dapagliflozin, were hypotension and dehydration, respectively.
CONCLUSION:

We concluded that in patients had ADRs after utilizing Canagliflozin versus Dapagliflozin where hypotension and dehydration were more common, respectively. ADRs in the control population was weight pick up had the negative impact and hypoglycemia was found to be more in the control population compared to canagliflozin and dapagliflozin endorsed bunches. Weight loss had a positive impact on canagliflozin and dapagliflozin-endorsed groups.
09 2025 08 22 2025 329 333 1 10.1097/LWW.0000000000001000 lww.com ovid.com true 2024-11-05 2025-07-15 http://creativecommons.org/licenses/by-nc-sa/4.0 10.4103/ijp.ijp_924_24 https://www.ovid.com/10.4103/ijp.ijp_924_24 https://www.ovid.com/10.4103/ijp.ijp_924_24 Clin Pharmacol Ther Pfster 89 621 2011 10.1038/clpt.2011.16 Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus N Engl J Med Anker 385 1451 2021 10.1056/NEJMoa2107038 Empaglifozin in heart failure with a preserved ejection fraction JAMA Petrie 323 1353 2020 10.1001/jama.2020.1906 Efect of dapaglifozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes Diabetologia Verma 61 2108 2018 10.1007/s00125-018-4670-7 SGLT2 inhibitorsand mechanisms of cardiovascularbenefit: a state-ofthe-art review Ann Intern Med Bersoff-Matcha 2019 10.7326/M19-0085 Fournier gangrene associated with sodium–glucose cotransporter-2 inhibitors: A review of spontaneous post marketing cases Lancet Wu 4 411 2016 Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis NEJM Neal 377 644 2017 10.1056/NEJMoa1611925 Canagliflozin and cardiovascular and renal events in type 2 diabetes Circulation Mahaffey 137 323 2018 10.1161/CIRCULATIONAHA.117.032038 Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) Circulation Fitchett 139 1384 2019 10.1161/CIRCULATIONAHA.118.037778 Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial